TARSUS PHARMACEUTICALS, INC. Debt Instrument, Unamortized Discount (Premium), Net
TARSUS PHARMACEUTICALS, INC. (TARS) had Debt Instrument, Unamortized Discount (Premium), Net of $0 as of 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet · last filed 2025-02-25
- 2024-12-31: Debt Instrument, Unamortized Discount (Premium), Net $0.00.
- 2024-09-30: Debt Instrument, Unamortized Discount (Premium), Net $0.00.
- 2024-06-30: Debt Instrument, Unamortized Discount (Premium), Net $0.00.
- 2024-03-31: Debt Instrument, Unamortized Discount (Premium), Net -$517.00K.
| Period end | Debt Instrument, Unamortized Discount (Premium), Net |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-25 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$517.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$438.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | -$358.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$289.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$226.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$174.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | -$127.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$79.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$32.00K 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |